Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: Research and clinical implications in erectile dysfunction

Trends in Endocrinology and Metabolism

Volumn 10, Issue 3, 1999, Pages 97-104

  Moreland, Robert B ^a   Goldstein, Irwin ^a   Kim, Noel N ^a   Traish, Abdulmaged ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ADRENERGIC ACTIVITY; CALCIUM CELL LEVEL; CEREBROVASCULAR DISEASE; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; HYDROLYSIS; PENIS ERECTION; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE RELAXATION;

EID: 0033013460     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(98)00127-1     Document Type: Review

References (51)

1. Saenz de Tejada I. In the physiology of erection, signposts to impotence. Contemp. Urol. 7:1992;52-68.
2. Andersson K-E., Wagner G. Physiology of erection. Physiol. Rev. 75:1995;191-236.
3. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. New Engl. J. Med. 338:1998;1397-1404.
4. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J. Urol. 151:1994;54-61.
5. Morales A., Heaton J.P.W., Johnston B., Adams M.A. Oral and topical treatment of erectile dysfunction: present and future. Urol. Clin. North Am. 22:1995;879-886.
6. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol. 155:1996;802-815.
7. Gingell J.C. New developments in self-injection therapy for erectile dysfunction. Br. J. Urol. 81:1998;599-603.
8. Burnett A. Nitric oxide in the penis: physiology and pathology. J. Urol. 157:1997;320-324.
9. Stief C.G., Noack T., Andersson K-E. Signal transduction in cavernous smooth muscle. World J. Urol. 15:1997;27-31.
10. Rembold C.M. Regulation of contraction and relaxation of arterial smooth muscle. Hypertension. 20:1991;129-137.
11. 2+ desensitization in vascular smooth muscle by activating myosin light chain phosphatase. J. Biol. Chem. 272:1997;5063-5068.
12. Chuang A.T., Strauss J.D., Murphy R.A., Steers W.D. Sildenafil, a type 5 c-GMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J. Urol. 160:1998;257-261.
13. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-745.
14. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36:1996;403-427.
15. Pyne N.J., Arshavsky V., Lochhead A. cGMP signal termination. Biochem. Soc. Trans. 24:1996;1019-1022.
16. Taher A., Meyer M., Stief C.G., Jonas U., Forssman W.G. Cyclic nucleotide phosphodiesterases in human cavernous smooth muscle. World J. Urol. 15:1997;32-35.
17. Fischer D.A., Smith J.F., Pillar J.S., St. Denis S.H., Cheng J.B. Isolation and characterization of PDE9A, a novel cGMP-specific phosphodiesterase. J. Biol. Chem. 273:1998;15559-15564.
18. Sonderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 273:1998;15553-15558.
19. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159:1998;2164-2171.
20. Boolell M.et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 8:1996;47-52.
21. Moreland R.B., Goldstein I., Traish A. Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum. Life Sci. 62:1998;PL309-PL318.
22. Francis S.H., Lincoln T.M., Corbin J.D. Characterization of a novel cGMP binding protein from rat lung. J. Biol. Chem. 255:1980;620-626.
23. Thomas M.K., Francis S.H., Corbin J.D. Characterization of a purified bovine lung cGMP-binding, c-GMP-specific phosphodiesterase. J. Biol. Chem. 265:1990;14964-14970.
24. McAllister-Lucas L.M.et al. The structure of a bovine lung cGMP-bind-ing site of cGMP-binding, c-GMP- specific phosphodiesterase deduced from a cDNA clone. J. Biol. Chem. 268:1993;22863-22873.
25. Francis S.H., Colbran J.L., McAllister-Lucas L.M., Corbin J.D. Zinc interactions and conserved motifs of the cGMP-binding, c-GMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J. Biol. Chem. 269:1994;22477-22480.
26. Stacey P., Rulten S., Dapling A., Phillips S.C. Molecular cloning and expression of human cGMP- binding cGMP-specific phosphodiesterase (PDE5). Biochem. Biophys. Res. Commun. 247:1998;249-254.
27. Turko I.V., Haik T.L., McAllister-Lucas L.M., Burns F., Francis S.H., Corbin J.D. Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding c-GMP-specific phosphodiesterase. J. Biol. Chem. 271:1996;22240-22244.
28. Turko I.V., Francis S.H., Corbin J.D. Binding of cGMP to both allosteric sites of cGMP-binding c-GMP-specific phosphodiesterase (PDE 5) is required for its phosphorylation. Biochem. J. 329:1998;505-510.
29. Beltman J., Sonnenberg W.K., Beavo J.A. The role of protein phosphorylation in the regulation of cyclic nucleotide phosphodiesterases. Mol. Cell. Biochem. 128:1993;239-253.
30. Wyatt T.A., Naftilan A.J., Francis S., Corbin J.D. ANF elicits phosphorylation of the cGMP phosphodi-esterase in vascular smooth muscle cells. Am. J. Physiol. 274:1998;H448-H455.
31. Turko I.V., Francis S.H., Corbin J.D. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding c-GMP-specific phosphodiesterase (PDE5) cGMP versus cAMP substrate selectivity. Biochemistry. 37:1998;4200-4205.
32. Turko I.V., Francis S.H., Corbin J.D. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding c-GMP-specific phosphodiesterase. J. Biol. Chem. 273:1998;6460-6466.
33. Rulten S.L.et al. Isolation of a human phosphodiesterase 5 cDNA and in situ analysis of its expression in human corpus cavernosum. J. Urol. 159:1998;92. (abstr. 351).
34. Sanchez L.S., de la Monte S.M., Filippov G., Jones R.C., Zapol W.M., Bloch K.D. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr. Res. 43:1998;163-168.
35. Kotera J.et al. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development. Eur. J. Biochem. 249:1997;434-442.
36. Steers W.D. Meta-analysis of the efficacy of sildenafil (Viagra™) in the treatment of severe erectile dysfunction. J. Urol. 159:1998;238. (abstr. 910).
37. Wagner G. Analysis of the efficacy of sildenafil (Viagra™) in the treatment of male erectile dysfunction in elderly patients. J. Urol. 159:1998;239. (abstr. 912).
38. Stief C.G., Uckert S., Becker A.J., Truss M.C., Jonas U. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J. Urol. 159:1998;1390-1395.
39. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil. A type 5 cGMP phosphodiesterase inhibitor and papverine on cyclic GMP and cyclic AMP levels in rabbit corpus cavernosum in vitro. Br. J. Urol. 79:1997;958-963.
40. Morales A., Gingell C., Collins M., Wicker P.A., Osterloh I.H. Clinical safety of oral sildenafil citrate (Viagra™) in the treatment of erectile dysfunction. Int. J. Impot. Res. 10:1998;69-74.
41. Carter A.J., Ballard S.A., Naylor A.M. Effect of the selective phosphodiesterase type 5 inhibitor on erectile function on the anesthetized dog. J. Urol. 160:1998;242-246.
42. Cooper J.D., Muirhead D.C., Taylor J.E., Baker P.R. Development of an assay for simultaneous determination of sildenafil (Viagra™) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high performance liquid chroma- tography. J. Chromatogr. B Biomed. Appl. 701:1997;87-95.
43. Fox D.A., Campbell M.L., Blocker Y.S. Functional alterations and apoptotic cell death in the retina following developmental or adult lead exposure. Neurotoxicology. 18:1997;645-664.
44. Boerth N.J., Dey N.B., Cornwell T.L., Lincoln T.M. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J. Vasc. Res. 34:1997;245-249.
45. Nehra A.et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J. Urol. 156:1996;1320-1329.
46. Moreland R.B. Is there a role of hypoxemia in penile fibrosis? Int. J. Impot. Res. 10:1998;113-120.
47. Kim N., Vardi Y., Padma-Nathan H., Daley J., Goldstein I., Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J. Clin. Invest. 91:1993;437-442.
48. Goldstein I., Berman J.R. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int. J. Impot. Res. 10(Suppl. 2):1998;84-90.
49. Laan E., Everaerd W. Physiological measures of vaginal vasocongestion. Int. J. Impot. Res. 10(Suppl. 2):1998;S107-S110.
50. Park K., Goldstein I., Andry C., Siroky M.B., Krane R.J., Azadzoi K.M. Vasculogenic female sexual dysfunction: the hemodynamic basis for vaginal engorgement insufficiency and clitoral erectile insufficiency. Int. J. Impot. Res. 9:1997;27-37.
51. Park K., Moreland R.B., Atala A., Goldstein I., Traish A.M. Characterization of phosphodiesterase activity in human clitoral corpus cavernosum smooth muscle cells in culture. Biochem. Biophys. Res. Commun. 249:1998;612-617.